Global Herpes Zoster Treatment Market 2019-2023

帯状疱疹治療薬の世界市場2019-2023

◆タイトル:Global Herpes Zoster Treatment Market 2019-2023
◆商品コード:IRTNTR30133
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年11月21日
◆ページ数:102
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥388,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥555,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

疾患管理のための革新的なワクチンの登場により、帯状疱疹治療薬の需要が高まっています。ワクチンが開発されるまで、帯状方針の治療は薬物治療しかありませんでした。
しかし、製薬業者は帯状疱疹の治療・予防するための新しい治療法を開発することに力を注いできました。
例えば、2017年10月、グラクソ・スミスクラインは帯状疱疹の治療薬であるShingrixの治療を開始しました。
Shingrixは、唯一の高齢者の帯状疱疹用に承認されたワクチンであるZOSTAVAXよりはるかに効果があります。
Technavioのアナリストは、帯状疱疹治療薬の世界市場が2023年までに約14%のCAGRで成長すると予測しています。

主な分析対象企業は、Abbott、GlaxoSmithKline、Merck、Novartisなどです。

当調査レポートでは、帯状疱疹治療薬の世界市場について調査・分析し、市場概要、市場環境、帯状疱疹治療薬市場規模、製品別(ワクチン接種、薬物療法)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。

・エグゼクティブサマリー
・調査範囲・調査手法
・帯状疱疹治療薬の世界市場概要
・帯状疱疹治療薬の世界市場環境
・帯状疱疹治療薬の世界市場動向
・帯状疱疹治療薬の世界市場規模
・帯状疱疹治療薬の世界市場:業界構造分析
・帯状疱疹治療薬の世界市場:製品別(ワクチン接種、薬物療法)
・帯状疱疹治療薬の世界市場:地域別市場規模・分析
・帯状疱疹治療薬の北米市場規模・予測
・帯状疱疹治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・帯状疱疹治療薬のアジア太平洋市場規模・予測
・帯状疱疹治療薬の主要国分析
・帯状疱疹治療薬の世界市場:意思決定フレームワーク
・帯状疱疹治療薬の世界市場:成長要因、課題
・帯状疱疹治療薬の世界市場:競争環境
・帯状疱疹治療薬の世界市場:関連企業情報(ベンダー分析)

101 pages, November 2018
About this market
With the emerging innovative vaccines for disease management, there is a growing demand for herpes zoster treatment drugs. Until the development of vaccines, the treatment for herpes zoster was dependent completely on drug therapies. However, vendors have been focusing on developing several new therapies for the treatment and prevention of shingles. For instance, in October 2017, Shingrix was launched by GlaxoSmithKline for the treatment of shingles. The vaccine is much more effective than ZOSTAVAX, which was the only approved vaccine for shingles in older adults. Technavio’s analysts have predicted that the herpes zoster treatment market will register a CAGR of almost 14% by 2023.
Market Overview
Rising incidence of herpes zoster
Factors such as exposure to ultraviolet radiation may suppress the cell-mediated immunity, which can be a major factor responsible for the growing incidence of herpes zoster. Patients being treated for cancer and affected with advanced HIV infection are at a greater risk of developing shingles, which is expected to boost the growth of the global herpes zoster treatment market.
Weak pipeline for herpes zoster
The number of herpes zoster pipeline agents are very limited despite the growing incidence of the infection worldwide, which is likely to hamper the growth of the global herpes zoster treatment market.
For the detailed list of factors that will drive and challenge the growth of the herpes zoster treatment market during the 2019-2023 period, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Abbott and GlaxoSmithKline, the competitive environment is quite intense. Factors such as the emerging innovative vaccines for disease management and rising incidence of herpes zoster, will provide considerable growth opportunities to herpes zoster treatment companies. Abbott, GlaxoSmithKline, Merck, and Novartis are some of the major companies covered in this report.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Vaccination – Market size and forecast 2018-2023
• Drug therapy – Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Abbott
• GlaxoSmithKline
• Merck
• Novartis
PART 15: APPENDIX
• Research methodology
• List of abbreviations
PART 16: EXPLORE TECHNAVIO

Exhibit 01: Global infectious disease treatment market
Exhibit 02: Segments of global infectious disease treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for the treatment of herpes zoster
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Vaccination – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Vaccination – Year-over-year growth 2019-2023 (%)
Exhibit 22: Drug therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Drug therapy – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 30: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 32: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 34: Key leading countries
Exhibit 35: Market opportunity
Exhibit 36: Impact of drivers and challenges
Exhibit 37: Vendor landscape
Exhibit 38: Landscape disruption
Exhibit 39: Vendors covered
Exhibit 40: Vendor classification
Exhibit 41: Market positioning of vendors
Exhibit 42: Abbott – Vendor overview
Exhibit 43: Abbott – Business segments
Exhibit 44: Abbott – Organizational developments
Exhibit 45: Abbott – Geographic focus
Exhibit 46: Abbott – Segment focus
Exhibit 47: Abbott – Key offerings
Exhibit 48: GlaxoSmithKline – Vendor overview
Exhibit 49: GlaxoSmithKline – Business segments
Exhibit 50: GlaxoSmithKline – Organizational developments
Exhibit 51: GlaxoSmithKline – Geographic focus
Exhibit 52: GlaxoSmithKline – Segment focus
Exhibit 53: GlaxoSmithKline – Key offerings
Exhibit 54: Merck – Vendor overview
Exhibit 55: Merck – Business segments
Exhibit 56: Merck – Organizational developments
Exhibit 57: Merck – Geographic focus
Exhibit 58: Merck – Key offerings
Exhibit 59: Novartis – Vendor overview
Exhibit 60: Novartis – Business segments
Exhibit 61: Novartis – Organizational developments
Exhibit 62: Novartis – Geographic focus
Exhibit 63: Novartis – Segment focus
Exhibit 64: Novartis – Key offerings



【掲載企業】

Abbott、GlaxoSmithKline、Merck、Novartis

★調査レポート[帯状疱疹治療薬の世界市場2019-2023] (Global Herpes Zoster Treatment Market 2019-2023 / IRTNTR30133)販売に関する免責事項
[帯状疱疹治療薬の世界市場2019-2023] (Global Herpes Zoster Treatment Market 2019-2023 / IRTNTR30133)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆